Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Regulated mRNA Transport02:22

Regulated mRNA Transport

6.4K
In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing...
6.4K
Regulation of Expression Occurs at Multiple Steps02:24

Regulation of Expression Occurs at Multiple Steps

23.3K
Gene expression can be regulated at almost every step from gene to protein. Transcription is the step that is most commonly regulated. This involves the binding of proteins to short regulatory sequences on the DNA. This association can either promote or inhibit the transcription of a gene associated with the respective sequence.
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
23.3K
  1. ホーム
  2. 臓がんにおけるミrnaの異常レベルは,腫瘍に関連したmrnaの翻訳を調節することによって,腫瘍の進行と関連している.
  1. ホーム
  2. 臓がんにおけるミrnaの異常レベルは,腫瘍に関連したmrnaの翻訳を調節することによって,腫瘍の進行と関連している.

関連する実験動画

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K

臓がんにおけるミRNAの異常レベルは,腫瘍に関連したmRNAの翻訳を調節することによって,腫瘍の進行と関連している.

Fadian Ding1,2,3,4, Yun Zhong1,2,3,4, Han Zhang1,2,3,4

  • 1Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Annals of medicine
|August 22, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

マイクロRNA (miRNA) は,腫瘍性タンパク質を阻害することで,臓がん細胞の行動を調節する. miRNAのバランスを回復することは,がんを誘発するmRNAサイクルを妨害し,治療の有効性を向上させるための鍵です.

キーワード:
3′-トランスレートされていない領域 (3′-UTR)mRNA翻訳マイクロRNA臓がん腫瘍関連タンパク質

さらに関連する動画

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

関連する実験動画

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

科学分野:

  • 腫瘍学
  • 分子生物学
  • 遺伝学

背景:

  • 臓がんは高度に悪性腫瘍で 治療方法は限られている.
  • マイクロRNA (miRNA) は,増殖,侵入,移動,アポトーシス,薬剤耐性を含む臓がん細胞機能の重要な調節因子である.

研究 の 目的:

  • 臓がんの進行における miRNA の役割を調査する.
  • 臓がんにおけるミRNAによって調節される重要なシグナル伝達経路と分子機構を特定する.

主な方法:

  • ミRNA標的タンパク質を特定するためにMetscape分析を使用した.
  • 濃縮された生物学的プロセス,シグナル伝達経路,およびタンパク質の局所化に焦点を当てました.

主要な成果:

  • miRNA標的タンパク質は細胞増殖,ミトーシス,および移動に関与する.
  • 主なシグナル伝達経路には,JAK/STAT,PI3K/AKT,およびWnt/β-cateninが含まれています.
  • miRNA標的領域における変異または異常な代替ポリアデニレーション (APA) は,腫瘍性mRNAの翻訳を強化する.

結論:

  • 複数のmiRNAが協働して 臓がんの進行を制御する.
  • miRNAシステムの回復をターゲットとする治療戦略は",mRNA-オンコゲン"サイクルを妨害するために不可欠です.